FDA opens re­view of CAR-T safe­ty af­ter iden­ti­fy­ing 19 cas­es of post-treat­ment blood can­cer

The FDA is re­view­ing the safe­ty of CAR-T ther­a­pies af­ter re­ports of pa­tients who de­vel­oped blood can­cers fol­low­ing treat­ment with the prod­ucts, an in­quiry that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER